

FLT1

Recombinant Human VEGFR-1 / FLT-1 (His Tag)

Catalog No.	CRH395A-His CRH395B-His	Quantity:	50 µg 100 µg
Alternate Names:	Vascular endothelial growth factor receptor 1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor		
Description:	Vascular endothelial growth factor receptor 1, also known as VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor and FLT1, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR-1 / FLT1 contains seven Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. VEGFR-1 / FLT1 is expressed mostly in normal lung, but also in placenta, liver, kidney, heart and brain tissues. It is specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR-1 / FLT1 is not expressed in tumor cell lines. VEGFR-1 / FLT1 is an essential receptor tyrosine kinase that regulates mammalian vascular development and embryogenesis. EGF-induced angiogenesis requires inverse regulation of VEGFR-1 and VEGFR-2 in tumor-associated endothelial cells. VEGFR-1 / FLT1 is a receptor for VEGF, VEGFB and PGF. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability.		
UniProt ID:	P17948		
Accession Number:	NP_002010.2		
Protein Construction:	A DNA sequence encoding the human FLT1 (Met1-Ile328) was expressed with a polyhistidine tag at the C-terminus.		
Source:	HEK293 Cells		
Molecular Weight:	The recombinant human FLT1 consists 313 amino acids and predicts a molecular mass of 35.6 kDa.		
Formulation:	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.		
Purity:	> 90 % as determined by SDS-PAGE.		
Endotoxin Level:	< 1.0 EU per µg protein as determined by the LAL method.		
Biological Activity:	Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC), the ED50 for this effect is typically 10-40 ng/mL in the presence of 10 ng/mL human VEGF165.		
Predicted N-terminal:	Ser 27		


Reconstitution:

Centrifuge vial prior to opening. Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial.
DO NOT VORTEX. Allow several minutes for complete reconstitution.


Storage & Stability:

Stable for up to 1 year from date of receipt at -20°C to -80°C
After reconstitution, store working aliquots at -20°C to -80°C.
Avoid repeated freeze-thaw cycles.

Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC), the ED50 for this effect is typically 10-40 ng/mL in the presence of 10 ng/mL human VEGF165.



SDS-PAGE



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com